Appendix C. Key to Acronyms
Updated
Reviewed
Study and Trial Names
| Acronym/Abbreviation | Name |
|---|---|
| ACTG | Advancing Clinical Therapeutics Globally or AIDS Clinical Trials Group |
| ADVANCE | Assessing Donor Variability And New Concepts in Eligibility |
| ANRS | National Agency for AIDS Research (France) |
| ARDENT | ACTG A5257 trial |
| ARTEMIS | Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| CANTOS | Canakinumab Anti-Inflammatory Thrombosis Outcomes Study |
| CARES | Cabotegravir and Rilpivirine Efficacy and Safety |
| CoRECT | Cooperative Re-Engagement Controlled Trial |
| D:A:D | Data Collection on Adverse Events of Anti-HIV Drugs |
| D2EFT | Dolutegravir and Darunavir Evaluation in Adults Failing Therapy |
| ECHO | Evidence for Contraceptive Options in HIV |
| ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
| FLAIR | First Long-Acting Injectable Regimen |
| HPTN | HIV Prevention Trials Network |
| LATITUDE | Long-Acting Therapy to Improve Treatment Success in Daily LifE |
| NA-ACCORD | North American AIDS Cohort Collaboration on Research and Design |
| NADIA | Nucleosides And Darunavir/Dolutegravir In Africa |
| PARTNER | Partners of People on ART: a New Evaluation of the Risks |
| RAPID | Rapid ART Program Initiative for HIV Diagnoses |
| RESPOND | International Cohort Consortium of Infectious Disease |
| REPRIEVE | Randomized Trial to Prevent Vascular Events in HIV |
| SMART | Strategies for Management of Antiretroviral Therapy |
| STaR | Study of Treatment and Reproductive Outcomes |
| START | Strategic Timing of AntiRetroviral Treatment |
| TEMPRANO | Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against tuberculosis in HIV-infected Adults |
| THRIVE | Targeting HIV Retention and Improved Viral Load Through Engagement |
| VACS | Veterans Aging Cohort Study |
| WIHS | Women’s Interagency HIV Study |
Appendix C. Key to Acronyms
Updated
Reviewed
Study and Trial Names
Acronym/Abbreviation | Name |
|---|---|
| ACTG | Advancing Clinical Therapeutics Globally or AIDS Clinical Trials Group |
| ADVANCE | Assessing Donor Variability And New Concepts in Eligibility |
| ANRS | National Agency for AIDS Research (France) |
| ARDENT | ACTG A5257 trial |
| ARTEMIS | Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| CANTOS | Canakinumab Anti-Inflammatory Thrombosis Outcomes Study |
| CARES | Cabotegravir and Rilpivirine Efficacy and Safety |
| CoRECT | Cooperative Re-Engagement Controlled Trial |
| D:A:D | Data Collection on Adverse Events of Anti-HIV Drugs |
| D2EFT | Dolutegravir and Darunavir Evaluation in Adults Failing Therapy |
| ECHO | Evidence for Contraceptive Options in HIV |
| ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
| FLAIR | First Long-Acting Injectable Regimen |
| HPTN | HIV Prevention Trials Network |
| LATITUDE | Long-Acting Therapy to Improve Treatment Success in Daily LifE |
| NA-ACCORD | North American AIDS Cohort Collaboration on Research and Design |
| NADIA | Nucleosides And Darunavir/Dolutegravir In Africa |
| PARTNER | Partners of People on ART: a New Evaluation of the Risks |
| RAPID | Rapid ART Program Initiative for HIV Diagnoses |
| RESPOND | International Cohort Consortium of Infectious Disease |
| REPRIEVE | Randomized Trial to Prevent Vascular Events in HIV |
| SMART | Strategies for Management of Antiretroviral Therapy |
| STaR | Study of Treatment and Reproductive Outcomes |
| START | Strategic Timing of AntiRetroviral Treatment |
| TEMPRANO | Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosisin HIV-infected Adults |
| THRIVE | Targeting HIV Retention and Improved Viral Load Through Engagement |
| VACS | Veterans Aging Cohort Study |
| WIHS | Women’s Interagency HIV Study |
Download Guidelines
- Section Only PDF (175.32 KB)
- Full Guideline PDF (7.93 MB)
- Recommendations Only PDF (340.89 KB)
- Tables Only PDF (2.87 MB)